RETRACTION

Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer [Retraction]


We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from Figures 2 and 4. Specifically,

- The western blot image for Figure 2B, MCF7/ADR, MDR1 appears to have been duplicated with the image for Figure 4C, MCF7/ADR, p62, which has been flipped.
- The image for Figure 4B, MCF7/ADR, siPTEN, has been duplicated with the image for Figure 4D, MCF/ADR, BBR.
- The western blot image for Figure 4C, MCF7/ADR, GAPDH, has been duplicated with the image for Figure 4E, MCF7/ADR, GAPDH.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As the findings could not be verified the Editor and Publisher made the decision to retract the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).